Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.
MRNA shows strong bullish momentum but is significantly overbought with multiple indicators suggesting limited near-term upside potential.
Valuation relies on pipeline potential rather than current earnings, with negative PE ratios and high PS ratio reflecting market optimism. Moderate PB ratio suggests reasonable asset-based valuation with target price of $70-75 contingent on successful pipeline execution.
